Radiopharm Theranostics Limited (NASDAQ:RADX) stock is trading higher on Monday, with a session volume of 21.33 million compared to the average volume of 26.81 thousand, as per data from Benzinga Pro.On Monday, Radiopharm Theranostics shared interim data from the first twelve patients in its U.S. Phase 2b imaging trial of RAD 101 in brain metastases.RAD 101 is a small-molecule imaging agent targeting fatty acid synthase (FASN) and radiolabelled with Fluorine-18 for the diagnosis of suspected recurrent brain ...